Dr Jane Wolstenholme
|Tel||+44 (0)1865 289269|
BA(Hons) (London), MSc (York), PhD (Nottingham)
Senior Health Economist, HERC
Jane Wolstenholme has 20 years of experience of conducting economic evaluations for health policy makers and exploring methodological issues relating to the design and analysis of economic evaluations. She has been a health economist at HERC since 1998.
Her main interests include designing and conducting economic evaluations alongside trials and cost-effectiveness models. She is principal investigator and co-applicant on a wide variety of funded research projects, across a number of disease areas and health-care technologies, including cancer, chronic kidney disease, obesity, mental health, point of care diagnostics. She is a health economics advisor for the RDS South Central and for the NIHR Diagnostics Evidence Co-Operative, Oxford. She supervises MSc and DPhil students. Jane has published widely and is co-author of a major OUP text book ‘Applied Methods of Cost-effectiveness Analysis in Health Care’.
Including health economic analysis in pilot studies: lessons learned from a cost-utility analysis within the PROSPECTIV pilot study
Burns RM. et al, (2017), Global and Regional Health Technology Assessment
Process mining routinely collected electronic health records to define real-life clinical pathways during chemotherapy.
Baker K. et al, (2017), International journal of medical informatics, 103, 32 - 41
Effect of oral dexamethasone without immediate antibiotics vs placebo on acute sore throat in adults: a Randomized Clinical Trial
Hayward GN. et al, (2017), Journal of the American Medical Association
Symptoms, unmet needs, psychological well-being and health status in survivors of prostate cancer: implications for redesigning follow-up.
Watson E. et al, (2016), BJU Int, 117, E10 - E19
Choosing an epidemiological model structure for the economic evaluation of non-communicable disease public health interventions
Briggs ADM. et al, (2016), Population Health Metrics, 14, 17 - 17